CY1110744T1 - Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c - Google Patents

Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c

Info

Publication number
CY1110744T1
CY1110744T1 CY20101100769T CY101100769T CY1110744T1 CY 1110744 T1 CY1110744 T1 CY 1110744T1 CY 20101100769 T CY20101100769 T CY 20101100769T CY 101100769 T CY101100769 T CY 101100769T CY 1110744 T1 CY1110744 T1 CY 1110744T1
Authority
CY
Cyprus
Prior art keywords
prophylactic
therapeutic treatment
combination
hepatitis
virus
Prior art date
Application number
CY20101100769T
Other languages
Greek (el)
English (en)
Inventor
Azpiroz Aintzane Zabaleta
Cuesta Francisco Borras
Valtueña Jesús Prieto
Ugarriza Pablo Sarobe
Sagastibelza Juan José Lasarte
Original Assignee
Proyecto De Biomedicina Cima, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200601563A external-priority patent/ES2334472B1/es
Application filed by Proyecto De Biomedicina Cima, S.L. filed Critical Proyecto De Biomedicina Cima, S.L.
Publication of CY1110744T1 publication Critical patent/CY1110744T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20101100769T 2005-10-07 2010-08-19 Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c CY1110744T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200502446 2005-10-07
ES200601563A ES2334472B1 (es) 2006-06-09 2006-06-09 Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c.
EP06830863A EP1949913B1 (en) 2005-10-07 2006-10-05 Immunostimulatory combination for the prophylactics and treatment of hepatitis c

Publications (1)

Publication Number Publication Date
CY1110744T1 true CY1110744T1 (el) 2015-06-10

Family

ID=37942331

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100769T CY1110744T1 (el) 2005-10-07 2010-08-19 Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c

Country Status (19)

Country Link
US (2) US20100047231A1 (https=)
EP (1) EP1949913B1 (https=)
JP (1) JP2009511452A (https=)
CN (1) CN101330928B (https=)
AT (1) ATE469657T1 (https=)
AU (1) AU2006301171B9 (https=)
BR (1) BRPI0616978A2 (https=)
CA (1) CA2625506C (https=)
CY (1) CY1110744T1 (https=)
DE (1) DE602006014720D1 (https=)
DK (1) DK1949913T3 (https=)
ES (1) ES2346570T3 (https=)
HR (1) HRP20100473T1 (https=)
PL (1) PL1949913T3 (https=)
PT (1) PT1949913E (https=)
RS (1) RS51402B (https=)
RU (1) RU2431499C2 (https=)
SI (1) SI1949913T1 (https=)
WO (1) WO2007042583A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2009059018A1 (en) * 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
JP4593783B2 (ja) * 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ 抗ｃ型肝炎ウイルス抗体およびその使用
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP2258712A3 (en) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
EP2572714A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations

Also Published As

Publication number Publication date
EP1949913A1 (en) 2008-07-30
DE602006014720D1 (de) 2010-07-15
AU2006301171B9 (en) 2012-03-29
AU2006301171B2 (en) 2011-10-27
US20100047231A1 (en) 2010-02-25
RU2431499C2 (ru) 2011-10-20
US20140056943A1 (en) 2014-02-27
CN101330928B (zh) 2012-11-14
BRPI0616978A2 (pt) 2011-07-05
CA2625506C (en) 2014-06-10
ATE469657T1 (de) 2010-06-15
AU2006301171A1 (en) 2007-04-19
RS51402B (sr) 2011-02-28
ES2346570T3 (es) 2010-10-18
PL1949913T3 (pl) 2010-10-29
WO2007042583A1 (es) 2007-04-19
JP2009511452A (ja) 2009-03-19
CA2625506A1 (en) 2007-04-19
EP1949913B1 (en) 2010-06-02
DK1949913T3 (da) 2010-10-04
HRP20100473T1 (hr) 2010-10-31
CN101330928A (zh) 2008-12-24
RU2008117328A (ru) 2009-11-20
PT1949913E (pt) 2010-08-24
SI1949913T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
MXPA05009580A (es) Vacuna contra el virus de la influenza.
EA200700904A1 (ru) Вакцины против вируса японского энцефалита и вируса западного нила
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
WO2008014521A8 (en) Improved vaccines and methods for using the same
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
BRPI0520330B8 (pt) adjuvante a base de ácido polinosínico-policitidílico
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EA201071316A1 (ru) Иммуномодуляция ингибиторами ингибиторов апоптоза
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
MX2010006984A (es) Vacunas contra la malaria.
WO2006071896A3 (en) Epitope-based sars vaccine
MY149395A (en) Pharmaceutical compound capable of induce immune protective response against dengue virus having the capsid protein of the dengue virus
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
WO2007120860A3 (en) Nanoemulsion vaccines